Inhibitor

(redirected from dipeptidyl peptidase-4 inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Legal, Wikipedia.

inhibitor

[in′hib·əd·ər]
(aerospace engineering)
A substance bonded, taped, or dip-dried onto a solid propellant to restrict the burning surface and to give direction to the burning process.
(chemistry)
A substance which is capable of stopping or retarding a chemical reaction; to be technically useful, it must be effective in low concentration.

Inhibitor

 

a circuit having m + n inputs and a single output, at which a signal can appear only when there are no signals on the m inputs (inhibiting). The other n inputs (principal) form one of the two logic connections, “AND” or “OR.” Inhibitors are used extensively in computers. They are very often understood to be a circuit having a single principal input and a single inhibiting input. A signal appears at the output of such a circuit when a signal is present on the principal input but there is none on the inhibiting input. Such an inhibitor is called an anticoincidence gate; its conventional representation is given in Figure 1.

Figure 1. Block diagram of an anticoincidence gate (inhibitor) with m — 1 and n 1:(A) principal input, (Q) inhibiting input, (Ga) anticoincidence gate

inhibitor

A substance added to paint to retard drying, skinning, mildew growth, etc. Also see corrosion inhibitor, inhibiting pigment, drying inhibitor.
References in periodicals archive ?
LOS ANGELES--The distinct possibility that using dipeptidyl peptidase-4 inhibitors to treat hyperglycemia in type 2 diabetic patients may substantially reduce the risk of major cardiovascular events has been raised in a comprehensive new meta-analysis of randomized controlled trials.
Also find individual revenue forecasts to 2025 for nine therapeutic submarkets at world level: - Human insulins and analogues - Dipeptidyl peptidase-4 inhibitors (DPP-4) - Biguanides - Glucagon-like peptide-1 receptor agonists (GLP-1) - Sulfonylureas.
of Birmingham, UK) and Grice, a medical writer from France, overview the new drugs and treatments developed recently to improve glycemic management for diabetic patients and how they can be translated into primary care, especially the incretin mimetics (glucagon-like peptide-1 agonists) and dipeptidyl peptidase-4 inhibitors.

Full browser ?